Effect of lactobacillus reuteri-derived probiotic nano-formulation on recurrent aphthous stomatitis: A Double-Blinded Randomized Clinical Trial

Abstract

Abstract Objectives We aimed to assess the therapeutic effects of a topical probiotic nano-formulation derived from Lactobacillus reuteri on treating recurrent aphthous stomatitis. Materials and Methods 60 participants were randomly allocated into two groups (control and probiotic). Probiotic group administered topical probiotic nano-formulation three times a day for seven days. The control group administered a standard analgesic oral rinse. The size of ulcer(s) and pain severity were recorded on days 0, 3, 5, and 7 after intervention. Results Before the intervention, the groups had no significant differences in pain severity and lesion size. Both groups reduced pain severity and lesion size during the intervention. After one week, the probiotic group had a significantly larger lesion size reduction (7.41 ± 1.79 mm) than the control (5.94 ± 1.59 mm). The probiotic group also significantly reduced pain severity (6.54 ± 1.56 scores) than the control (5.82 ± 1.66 scores). Conclusions Applying topical probiotic nano-formulation derived from Lactobacillus reuteri three times a day decreased lesion size and pain severity in RAS patients faster than the local analgesic oral rinse. Clinical relevance : Lactobacillus reuteri-derived probiotic nano-formulation might be a promising treatment option for RAS.